Clinical Trial Update: Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study [NA]

View source ↗

Summary

A prospective, multicenter real-world study assessing the efficacy and safety of switching to Ivarmacitinib in adults with moderate-to-severe atopic dermatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Ivarmacitinib

Snippet

Sponsor: Peking University People's Hospital | Conditions: Atopic Dermatitis (AD) | NA | Status: NOT_YET_RECRUITING